Two disclosures revealed new small-molecule inhibitor programs from established organizations: Kymera Therapeutics reported discovery of STAT6 inhibitors aimed at oncology and inflammatory diseases, while Boehringer Ingelheim described cGAS inhibitors with potential in autoinflammatory and fibrotic disorders. Both programs expand efforts to drug previously challenging intracellular signaling nodes. Kymera’s STAT6 program targets transcriptional pathways implicated in tumor and immune biology; Boehringer’s cGAS inhibitors pursue modulation of innate immune DNA sensing implicated in interferonopathies and fibrosis. Early-stage programs will require translational biomarkers and careful safety profiling given the immune‑modulatory mechanisms.